Intuitive Surgical, Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +35

Intuitive Surgical, Inc. $ISRG Shares Purchased by Fjarde AP Fonden ...

📈 Fjarde AP Fonden increased its ISRG stake by 57.7% to $59.68 million in Q1, signaling strong institutional confidence.

📉 EVP Gary Loeb sold 400 shares worth $169,656 and Director Amy Ladd sold 119 shares worth $55,156 under Rule 10b5-1 plans.

💰 Q1 revenue reached $2.77 billion, a 23% year-over-year increase that beat analyst estimates of $2.62 billion.

📊 EPS for the quarter was $2.50, surpassing the consensus estimate of $2.08 by $0.42.

🎯 The company achieved a net margin of 28.15% and a return on equity of 15.98%.

📉 Zacks Research downgraded ISRG from Strong-Buy to Hold in late March.

📈 TD Cowen lowered its price target to $585 but maintained a Buy rating as of April 22nd.

🏦 Mizuho set a neutral price target of $525 on April 13th.

📉 Insider selling totaled over $3 million in the last quarter, representing 0.60% of total stock ownership.

📈 Institutional investors own 83.64% of the company's outstanding shares.

📉 The stock trades at a P/E ratio of 51.64 with a market capitalization of $150.88 billion.

📉 ISRG stock opened at $426.01, trading below its 200-day moving average of $480.00.

📈 The consensus analyst price target is $573.42 based on a Moderate Buy rating.

🏥 Intuitive Surgical focuses on robotic-assisted surgical systems like the da Vinci platform.

📉 Wall Street Zen upgraded the stock from Hold to Buy in mid-June.

Bullish Signals
  • Revenue of $2.77 billion beat analyst estimates by $150 million, demonstrating strong demand for robotic surgical systems.
  • EPS of $2.50 significantly exceeded the consensus estimate of $2.08, indicating robust operational performance.
  • Fjarde AP Fonden, a major Swedish pension fund, increased its stake by 57.7%, validating long-term investment thesis.
  • Net margin expanded to 28.15% and return on equity reached 15.98%, reflecting high profitability.
  • TD Cowen maintains a Buy rating despite lowering the price target, suggesting continued confidence in the business model.
  • Wall Street Zen upgraded the stock from Hold to Buy in June, adding to the bullish analyst consensus.
Risk Factors
  • Zacks Research downgraded the stock from Strong-Buy to Hold, citing potential valuation concerns or slowing growth.
  • Mizuho assigned a Neutral rating with a $525 price target, which is below the current trading price of ~$426 but implies limited upside.
  • Significant insider selling occurred in Q1, with executives and directors reducing holdings by over $3 million combined.
  • The stock trades at a high P/E ratio of 51.64, which may limit upside if growth rates decelerate.
  • Recent price action shows the stock trading below its 200-day moving average of $480, indicating short-term weakness.
Full Analysis
Intuitive Surgical (ISRG) saw significant institutional activity in the first quarter, led by Fjarde AP Fonden boosting its stake by 57.7% to a value of $59.68 million. Several other smaller investors also increased or initiated positions, while institutional ownership remains high at 83.64%. Conversely, insider selling was notable, with EVP Gary Loeb and Director Amy Ladd reducing their holdings under pre-arranged trading plans, totaling over $3 million in sales during the quarter. Analyst sentiment for ISRG is mixed but generally positive, with a consensus price target of $573.42 based on 19 Buy ratings versus 7 Hold and 1 Sell. Recent reports include TD Cowen lowering its target to $585 while maintaining a Buy rating, Mizuho setting a neutral target at $525, and Zacks Research downgrading the stock from Strong-Buy to Hold. The average analyst price target reflects a moderate buy consensus despite some recent downgrades. Financially, Intuitive Surgical reported strong Q1 results with revenue of $2.77 billion, beating estimates by 5.7% and growing 23% year-over-year. The company posted $2.50 EPS, significantly above the $2.08 consensus, resulting in a net margin of 28.15%. With a market cap of $150.88 billion and a P/E ratio of 51.64, the stock trades above its 200-day moving average but below its 52-week high, reflecting recent volatility.